Compare VIOT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | BDTX |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 116.8M |
| IPO Year | 2018 | 2020 |
| Metric | VIOT | BDTX |
|---|---|---|
| Price | $1.41 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 277.9K | ★ 564.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 32.45 |
| EPS | N/A | ★ 0.65 |
| Revenue | N/A | N/A |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | $3.56 | ★ $3.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.18 | $1.20 |
| 52 Week High | $4.33 | $4.94 |
| Indicator | VIOT | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 40.78 |
| Support Level | $1.22 | $1.93 |
| Resistance Level | $1.49 | $2.67 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 75.00 | 26.76 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.